SINGAPORE, April 23, 2025 (Korea Bizwire) – Sidra Capital, a leading global manager of Shariah-compliant alternative investments, has announced the launch of an Australian private credit investment fund focusing on the mining and energy sector in Australia. The fund, Sidra Asia Pacific Private Investments Sub-Fund I, will be managed by Sidra Capital’s Singapore team, who have [...]
Release of Full First Quarter Results and Earnings Call to Take Place on May 12, 2025 ST. GALLEN, Switzerland, April 22, 2025 (Korea Bizwire) – Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors today announced, in conjunction with [...]
ST. GALLEN, Switzerland, April 22, 2025 (Korea Bizwire) – Sportradar Group AG (Nasdaq: SRAD) (“Sportradar” or the “Company”) today announced a proposed secondary public offering of an aggregate of 23,000,000 Class A ordinary shares of the Company (the “Secondary Offering”) by an affiliate of Canada Pension Plan Investment Board, an affiliate of Technology Crossover Ventures, [...]
Report highlights implementation of responsible sourcing framework, including the assessment of 844 suppliers, as well as progress on other sustainability efforts ARLINGTON, Va., April 22, 2025 (Korea Bizwire) — Fluence Energy, Inc. (“Fluence”) (NASDAQ: FLNC), a global market leader delivering intelligent energy storage, services, and asset optimization software, today released its fiscal year 2024 Sustainability [...]
First Half Fiscal 2025 Results Issy-les-Moulineaux, France – April 17, 2025 Pluxee continues to deliver solid business and financial performance in H1 and raises its Fiscal 2025 Recurring EBITDA margin objective First Half Fiscal 2025 highlights Continued execution of the Group’s 3-year strategic growth plan, successfully advancing key initiatives, including M&A, while consistently driving sustainable and profitable growth Robust business dynamics [...]
PHOENIX, April 16, 2025 (Korea Bizwire) – WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space solutions, today announced that it will release its first quarter 2025 financial results on May 1, 2025, after market close. The Company’s management team will host a conference call and webcast on May 1, [...]
Ad hoc announcement pursuant to Art. 53 LR Baar, Switzerland, April 16, 2025 At the Annual General Meeting held on April 16, 2025, in Zug, the shareholders of Ascom Holding AG approved by a large majority all proposals presented by the Board of Directors. 54 shareholders attended the Annual General Meeting. In total, 20’238’079 registered [...]
Turin, 16th April 2025 (Korea Bizwire) – Iveco Group N.V. (EXM: IVG) (the Company) announces that its shareholders approved all the resolutions proposed by the Board of Directors (the Board) at its Annual General Meeting (AGM) held today in Amsterdam, the Netherlands. At the AGM, the shareholders: adopted the 2024 Annual Financial Statements; approved the proposal [...]
All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for re-election confirmed Dividend of CHF 0.60 per registered dividend-paying share approved, representing 24% of core net income Basel, April 15, 2025 (Korea Bizwire) – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals [...]
![[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US](http://koreabizwire.com/wp/wp-content/uploads/2024/01/Sandoz-Holzkirchen.png "[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US")
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseases Despite FDA approval nearly a decade ago, [...]